

dihydrogen phosphoric, phthalic, polygalactouronic, propionic, salicylic, stearic, succinic, sulfamic, sulfanilic, sulfonic, sulfuric, tannic, tartaric, teoclic and toluenesulfonic.

23. (Original) A substituted amine according to claim 1 which is selected from the group consisting of:

N^1 -[(1S,2S)-1-(3,5-difluorobenzyl)-3-(hexylamino)-2-hydroxypropyl]- N^3,N^3 -dipropylisophthalamide,


N^1 -[(1S,2S)-3-(benzylamino)-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl- N^3,N^3 -dipropylisophthalamide,

N^1 -{(1S,2S)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-methyl- N^3,N^3 -dipropylisophthalamide, and

N^1 -(1S,2S)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-2-(isobutylamino)-1-methyl-2-oxoethyl]amino}propyl)- N^3,N^3 -dipropylisophthalamide.

24. (Original) A method of treating a patient who has, or in preventing a patient from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating patients with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's

disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment which comprises administration of a therapeutically effective amount of a compound selected from the group consisting of a substituted amine of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1, and pharmaceutically acceptable salts thereof.

25. (Original) A method of treatment according to claim 24 where the disease is Alzheimer's disease.

26. (Original) A method of treatment according to claim 24 where the method is helping prevent or delay the onset of Alzheimer's disease.

27. (Original) A method of treatment according to claim 24 where the disease is mild cognitive impairment.

28. (Original) A method of treatment according to claim 24 where the disease is Down's syndrome.

29. (Original) A method of treatment according to claim 24 where the disease is Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type.

30. (Original) A method of treatment according to claim 24 where the disease is cerebral amyloid angiopathy.

31. (Original) A method of treatment according to claim 24 where the disease is degenerative dementias.

32. (Original) A method of treatment according to claim 24 where the disease is diffuse Lewy body type of Alzheimer's disease.

33. (Original) A method of treatment according to claim 24 where the method is treating an existing disease.

34. (Original) A method of treatment according to claim 24 where the method is preventing a disease from developing.

35. (Original) A method of treatment according to claim 24 where the therapeutically effective amount for oral administration is from about 0.1 mg/day to about 1,000 mg/day; for parenteral, sublingual, intranasal, intrathecal administration is from about 0.5 to about 100 mg/day; for depo administration and implants is from about 0.5 mg/day to about 50 mg/day; for topical administration is from about 0.5 mg/day to about 200 mg/day; for rectal administration is from about 0.5 mg to about 500 mg.

36. (Original) A method of treatment according to claim 35 where the therapeutically effective amount is for oral administration is from about 1 mg/day to about 100 mg/day and for parenteral administration is from about 5 to about 50 mg daily.

37. (Original) A method of treatment according to claim 36 where the therapeutically effective amount for oral administration is from about 5 mg/day to about 50 mg/day.

38. (Original) A method of treating a patient who has, or in preventing a patient from getting, a disease or condition selected from the group consisting of Alzheimer's disease, for helping prevent or delay the onset of Alzheimer's disease, for treating patients with mild cognitive impairment (MCI) and preventing or delaying the onset of Alzheimer's disease in those who would progress from MCI to AD, for treating Down's syndrome, for treating humans who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, for treating cerebral amyloid angiopathy and preventing its potential consequences, i.e. single and recurrent lobar hemorrhages, for treating other degenerative dementias, including dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, diffuse Lewy body type of Alzheimer's disease and who is in need of such treatment which comprises administration of a therapeutically effective amount of a compound selected from the group consisting of:


N¹-[(1S,2S)-1-(3,5-difluorobenzyl)-3-(hexylamino)-2-hydroxypropyl]-N³,N³-dipropylisophthalamide,

N¹-[(1S,2S)-3-(benzylamino)-1-(3,5-difluorobenzyl)-2-hydroxypropyl]-5-methyl-N³,N³-dipropylisophthalamide,

N¹-{(1S,2S)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}-5-methyl-N³,N³-dipropylisophthalamide, and


N¹-(1S,2S)-1-(3,5-difluorobenzyl)-2-hydroxy-3-{[(1S)-2-(isobutylamino)-1-methyl-2-oxoethyl]amino}propyl)-N³,N³-dipropylisophthalamide; and
a pharmaceutically acceptable salt thereof.

39. (Original) A pharmaceutical composition which comprises a substituted amine of formula (X)



where R₁, R₂, R₃, R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

40. (Original) A method for inhibiting beta-secretase activity, comprising exposing said beta-secretase to an effective inhibitory amount of a compound of formula (X)



where R₁, R₂, R₃, R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof.


41. (Original) The method of claim 40, wherein said beta-secretase is exposed to said compound *in vitro*.

42. (Original) The method of claim 40, wherein said beta-secretase is exposed to said compound in a cell.

43. (Original) The method of claim 42, wherein said cell is in an animal.

44. (Original) The method of claim 43, wherein said animal is a human.

45. (Original) A method for inhibiting cleavage of amyloid precursor protein (APP), in a reaction mixture, at a site between Met596 and Asp597, numbered for the APP-695 amino acid isotype; or at a corresponding site of an isotype or mutant thereof, comprising exposing said reaction mixture to an effective inhibitory amount of a compound of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof.

46. (Original) The method of claim 45, wherein said cleavage site is between Met652 and Asp653, numbered for the APP-751 isotype; between Met 671 and Asp 672, numbered for the


APP-770 isotype; between Leu596 and Asp597 of the APP-695 Swedish Mutation; between Leu652 and Asp653 of the APP-751 Swedish Mutation; or between Leu671 and Asp672 of the APP-770 Swedish Mutation.

47. (Original) The method of claim 45, wherein said reaction mixture is exposed *in vitro*.

48. (Original) The method of claim 47, wherein said reaction mixture is exposed in a cell.

49. (Original) The method of claim 48, wherein said cell is a human cell.

50. (Original) A method for inhibiting production of amyloid beta peptide (A beta) in a cell, comprising administering to said cell an effective inhibitory amount of a compound of formula (X)




where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof.

51. (Original) The method of claim 50, wherein said administering is to an animal.

52. (Original) The method of claim 51, wherein said administering is to a human.


53. (Original) A method for inhibiting the production of beta-amyloid plaque in an animal, comprising administering to said animal an effective inhibitory amount of a compound of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof.

54. (Original) The method of claim 53, wherein said animal is a human.

55. (Original) A method for treating or preventing a disease characterized by beta-amyloid deposits in the brain comprising administering to a patient an effective therapeutic amount of a compound of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof.

56. (Original) The method of claim 55, wherein said therapeutic amount is in the range of from about 0.1 to about 1000 mg/day.

57. (Currently Amended) The method of claim 55, wherein said ~~therapeutic~~ therapeutic amount is in the range of from about 15 to about 1500 mg/day.


58. (Currently Amended) The method of claim 57, wherein said ~~therapeutic~~ therapeutic amount is in the range of from about 1 to about 100 mg/day.

59. (Currently Amended) The method of claim 58, wherein said ~~therapeutic~~ therapeutic amount is in the range of from about 5 to about 50 mg/day.

60. (Original) The method of claim 55, wherein said disease is Alzheimer's disease.


61. (Original) The method of claim 55, wherein said disease is Mild Cognitive Impairment, Down's Syndrome, or Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type.

62. (Original) A composition comprising beta-secretase complexed with a compound of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1,
or a pharmaceutically acceptable salt thereof.

63. (Original) A method for producing a beta-secretase complex comprising: exposing beta-secretase, in a reaction mixture under conditions suitable for the production of said complex, to a compound of formula (X)




where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1,
or a pharmaceutically acceptable salt thereof.

64. (Original) The method of claim 63, where said exposing is *in vitro*.

65. (Original) The method of claim 63, wherein said reaction mixture is a cell.


66. (Original) A kit comprising component parts capable of being assembled, wherein at least one component part comprises, enclosed in a container, a compound of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof.

67. (Original) The kit of claim 66, wherein said compound is lyophilized and at least one further component part comprises a diluent.

68. (Original) A kit comprising a plurality of containers, each container comprising one or more unit dose of a compound of formula (X)




where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof.

69. (Original) The kit of claim 68, wherein each container is adapted for oral delivery and comprises a tablet, gel, or capsule.

70. (Currently Amended) The kit of claim 69, wherein each container is adapted for ~~parenteral~~ parenteral delivery and comprises a depot product, syringe, ampoule, or vial.


71. (Original) The kit of claim 69, wherein each container is adapted for topical delivery and comprises a patch, medipad, ointment, or cream.

72. (Currently Amended) A kit comprising one or more therapeutic agent selected from the group consisting of an antioxidant, an ~~anti-inflammatory~~, anti-inflammatory, a gamma secretase inhibitor, a neurotrophic agent, an acetylcholinesterase inhibitor, a statin, an A beta peptide, and an anti-A beta antibody; and
a compound of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1,
or a pharmaceutically acceptable salt thereof.


73. (Original) A composition comprising an inert diluent or edible carrier; and
a compound of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof.


74. (Original) The composition of claim 73, wherein said carrier is an oil.

75. (Original) A composition comprising a binder, excipient, disintegrating agent, lubricant, or gildant; and a compound of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1, or a pharmaceutically acceptable salt thereof..

76. (Original) A composition comprising a compound of formula (X)



where R_1 , R_2 , R_3 , R_N and R_C are as defined in claim 1,
or a pharmaceutically acceptable salt thereof,
and where the compound is disposed in a cream, ointment, or
patch.